
AKT inhibitor shows signs of effectiveness in a patient trial matching drugs to tumor gene mutations
In a trial matching new treatments to cancer patients based on the genetic makeup of their tumors, the tumors shrank in 22% of the patients treated with the AKT inhibitor drug ipatasertib. This included patients with breast ...
Oct 26, 2022
0
10